AR123329A1 - VACCINES AGAINST COVID-19 WITH SQUALENE EMULSION ADJUVANTS CONTAINING TOCOPHEROL - Google Patents
VACCINES AGAINST COVID-19 WITH SQUALENE EMULSION ADJUVANTS CONTAINING TOCOPHEROLInfo
- Publication number
- AR123329A1 AR123329A1 ARP210102379A ARP210102379A AR123329A1 AR 123329 A1 AR123329 A1 AR 123329A1 AR P210102379 A ARP210102379 A AR P210102379A AR P210102379 A ARP210102379 A AR P210102379A AR 123329 A1 AR123329 A1 AR 123329A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- residues
- cov
- sequence
- sars
- Prior art date
Links
Abstract
Se proporcionan vacunas novedosas para tratamiento profiláctico de las infecciones por SARS-CoV-2 y COVID-19 y métodos para elaborar las vacunas, en donde las vacunas contienen una emulsión de aceite en agua que comprende tocoferol y escualeno. Reivindicación 1: Una composición inmunogénica que comprende (a) una, dos, tres o más proteínas recombinantes de SARS-CoV-2, en donde una o más de las proteínas es un trímero de un polipéptido que comprende, desde el extremo N terminal al extremo C terminal, (i) una secuencia que es al menos 95% idéntica a los restos 19 - 1243 de SEQ ID Nº 10, en donde los restos GSAS (SEQ ID Nº 6) en las posiciones 687 - 690 de SEQ ID Nº 10 y los restos PP en las posiciones 991 y 992 de SEQ ID Nº 10 se mantienen en la secuencia; y (ii) un dominio de trimerización, en donde el dominio de trimerización comprende SEQ ID Nº 7; y (b) un coadyuvante, en donde el coadyuvante es una emulsión de aceite en agua que comprende tocoferol y escualeno. Reivindicación 2: Una composición inmunogénica que comprende (a) una, dos, tres o más proteínas S recombinantes de SARS-CoV-2, cada una producida por un método que comprende introducir en células de insecto un vector baculoviral para expresar un polipéptido que comprende, del extremo N terminal al extremo C terminal, (i) un péptido señal derivado de una proteína de insecto o baculoviral, (ii) una secuencia que es al menos 95% idéntica a los restos 19 - 1243 de SEQ ID Nº 10, en donde los restos GSAS (SEQ ID Nº 6) en las posiciones 687 - 690 de SEQ ID Nº 10 y los restos PP en las posiciones 991 y 992 de SEQ ID Nº 10 se mantienen en la secuencia; y (iii) un dominio de trimerización, en donde el dominio de trimerización comprende SEQ ID Nº 7, cultivar las células de insecto en condiciones que permitan la expresión y trimerización del polipéptido, y aislar la proteína S recombinante de SARS-CoV-2 del cultivo, en donde la proteína S recombinante de SARS-CoV-2 es un trímero del polipéptido, sin la secuencia señal; y (b) un coadyuvante, en donde el coadyuvante es una emulsión de aceite en agua que comprende tocoferol y escualeno.Novel vaccines for prophylactic treatment of SARS-CoV-2 and COVID-19 infections and methods of making the vaccines are provided, wherein the vaccines contain an oil-in-water emulsion comprising tocopherol and squalene. Claim 1: An immunogenic composition comprising (a) one, two, three or more SARS-CoV-2 recombinant proteins, wherein one or more of the proteins is a trimer of a polypeptide comprising, from the N-terminus to the C-terminus, (i) a sequence that is at least 95% identical to residues 19-1243 of SEQ ID NO: 10, wherein residues GSAS (SEQ ID NO: 6) at positions 687-690 of SEQ ID NO: 10 and the PP residues at positions 991 and 992 of SEQ ID NO: 10 remain in the sequence; and (ii) a trimerization domain, wherein the trimerization domain comprises SEQ ID NO: 7; and (b) a builder, wherein the builder is an oil-in-water emulsion comprising tocopherol and squalene. Claim 2: An immunogenic composition comprising (a) one, two, three or more recombinant SARS-CoV-2 S proteins, each produced by a method comprising introducing into insect cells a baculoviral vector to express a polypeptide comprising , from the N-terminus to the C-terminus, (i) a signal peptide derived from an insect or baculoviral protein, (ii) a sequence that is at least 95% identical to residues 19-1243 of SEQ ID NO: 10, in where the GSAS residues (SEQ ID No. 6) at positions 687-690 of SEQ ID No. 10 and the PP residues at positions 991 and 992 of SEQ ID No. 10 remain in sequence; and (iii) a trimerization domain, wherein the trimerization domain comprises SEQ ID NO: 7, culturing the insect cells under conditions that allow expression and trimerization of the polypeptide, and isolating recombinant SARS-CoV-2 protein S from the culture, wherein the recombinant SARS-CoV-2 protein S is a trimer of the polypeptide, without the signal sequence; and (b) a builder, wherein the builder is an oil-in-water emulsion comprising tocopherol and squalene.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069171P | 2020-08-24 | 2020-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123329A1 true AR123329A1 (en) | 2022-11-23 |
Family
ID=84578079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102379A AR123329A1 (en) | 2020-08-24 | 2021-08-23 | VACCINES AGAINST COVID-19 WITH SQUALENE EMULSION ADJUVANTS CONTAINING TOCOPHEROL |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR123329A1 (en) |
-
2021
- 2021-08-23 AR ARP210102379A patent/AR123329A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sugawara et al. | Development of Vero cell-derived inactivated Japanese encephalitis vaccine | |
| CL2020000039A1 (en) | Fusion proteins, recombinant bacteria and methods of using recombinant bacteria. (divisional request 201700647) | |
| CN110862435B (en) | African swine fever CTL epitope polypeptide and application thereof | |
| Cai et al. | Identification of a Nosema bombycis (Microsporidia) spore wall protein corresponding to spore phagocytosis | |
| AR113455A1 (en) | IMMUNOMODULATING PROTEINS OF ICOS LIGAND VARIANTS AND RELATED COMPOSITIONS AND METHODS | |
| ES2102815T3 (en) | PROCEDURE FOR OBTAINING NATIVE ECTODOMINES, OLIGOMERS, GLYCOSILATES OF VIRAL MEMBRANE PROTEINS, THEIR USE, ESPECIALLY AS A VACCINE AGAINST HIV. | |
| ES2150416T3 (en) | DEFECTIVE VIRAL VACCINE PRODUCED BY A CELL LINE SUPPLEMENTED IN TRANS. | |
| AR003425A1 (en) | RECOMBINANT MAPACHE POXVIRUS, VACCINE FOR USE IN CATS AND USE OF POXVIRUS TO PREPARE A VACCINE USEFUL TO AVOID OR DECREASE THE DISEASE CAUSED BY THE FELINE IMMUNODEFICIENCY VIRUS (IVF) | |
| Vyas et al. | Identification of peptidases in highly pathogenic vs. weakly pathogenic Naegleria fowleri amebae | |
| CL2009001249A1 (en) | Use of an endopolygalacturonase pectonylitic enzyme to treat pureed fruits or vegetables; procedure for enzymatic treatment; DNA molecule that encodes a polypeptide with endopolygalacturonase activity; polypeptide, expression vector and host cell comprising said sequence. | |
| CO2022018888A2 (en) | A cocktail of peptides | |
| US9382546B2 (en) | Process for making oligopeptides | |
| Gomes et al. | Role of Synadenium grantii latex proteases in nematicidal activity on Meloidogyne incognita and Panagrellus redivivus | |
| Reinhardt et al. | Neutrophil and eosinophil chemotactic factors in the excretory/secretory products of sheep abomasal nematode parasites: NCF and ECF in abomasal nematodes | |
| PE20020572A1 (en) | PREPARATIONS TO ENHANCE THE IMMUNOGENICITY OF UNIMMUNOGENIC ANTIGENS | |
| AR123158A1 (en) | LIGAND FUSION PROTEINS FOR FLT3 AND METHODS OF USE | |
| AR123329A1 (en) | VACCINES AGAINST COVID-19 WITH SQUALENE EMULSION ADJUVANTS CONTAINING TOCOPHEROL | |
| Li et al. | Siganus oramin recombinant L-amino acid oxidase is lethal to Cryptocaryon irritans | |
| O'donnell et al. | A novel host-protective antigen from Trichostrongylus colubriformis | |
| CO2023003453A2 (en) | Coronavirus Immunogenic Fusion Proteins and Related Methods | |
| CN109207502B (en) | Porcine mycoplasma pneumonia and porcine circovirus type 2 recombinant protein and preparation of bivalent vaccine | |
| Bernardes et al. | Sm16, a Schistosoma mansoni immunomodulatory protein, fails to elicit a protective immune response and does not have an essential role in parasite survival in the definitive host | |
| WO2018115509A3 (en) | New flavivirus vaccine | |
| Oliver et al. | Analysis of the effects of Perkinsus marinus proteases on plasma proteins of the Eastern oyster (Crassostrea virginica) and the Pacific oyster (Crassostrea gigas) | |
| Wang et al. | A new microneme protein of Neospora caninum, NcMIC8 is involved in host cell invasion |